Cogent Biosciences, Inc. (COGT)
NASDAQ: COGT · Real-Time Price · USD
34.96
-0.42 (-1.19%)
At close: May 29, 2026, 4:00 PM EDT
35.04
+0.08 (0.23%)
After-hours: May 29, 2026, 7:47 PM EDT
Cogent Biosciences Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
258
Market Cap
5.98B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | 7.87M | -14.63M | -65.02% |
| Dec 31, 2019 | 22.50M | 12.77M | 131.14% |
| Dec 31, 2018 | 9.73M | 1.37M | 16.44% |
| Dec 31, 2017 | 8.36M | 2.01M | 31.55% |
| Dec 31, 2016 | 6.36M | 3.37M | 112.83% |
| Dec 31, 2015 | 2.99M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| PTC Therapeutics | 827.11M |
| TG Therapeutics | 700.35M |
| Mirum Pharmaceuticals | 569.61M |
| Rhythm Pharmaceuticals | 217.17M |
| Protagonist Therapeutics | 74.06M |
| Centessa Pharmaceuticals | 15.00M |
COGT News
- 9 hours ago - Cogent Biosciences Announces Detailed Clinical Data from PEAK Phase 3 Trial with Bezuclastinib in Combination with Sunitinib in Gastrointestinal Stromal Tumors (GIST) at 2026 American Society of Clinical Oncology (ASCO) Annual Meeting - GlobeNewsWire
- 2 days ago - Cogent Biosciences announces FDA acceptance of bezuclastinib NDA - TheFly
- 2 days ago - Cogent Biosciences Announces FDA Acceptance of New Drug Application (NDA) with Priority Review for Bezuclastinib in Combination with Sunitinib for Patients with GIST - GlobeNewsWire
- 3 days ago - Cogent Biosciences Announces Participation in the 2026 Jefferies Global Healthcare Conference - GlobeNewsWire
- 18 days ago - Cogent Biosciences Announces Multiple Presentations at the European Hematology Association (EHA) 2026 Congress - GlobeNewsWire
- 23 days ago - Cogent Biosciences price target raised to $55 from $52 at H.C. Wainwright - TheFly
- 25 days ago - Cogent Biosciences Reports Recent Business Highlights and First Quarter 2026 Financial Results - GlobeNewsWire
- 25 days ago - Cogent Biosciences Earnings release: Q1 2026 - Filings